GenVec, Inc.  

(Public, NASDAQ:GNVC)   Watch this stock  
Find more results for GNVC
2.03
+0.03 (1.50%)
Real-time:   12:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.99 - 2.06
52 week 1.83 - 3.49
Open 1.99
Vol / Avg. 9,481.00/12,752.00
Mkt cap 26.29M
P/E     -
Div/yield     -
EPS -0.65
Shares 12.95M
Beta 1.59
Inst. own 18%
Jul 11, 2012
GenVec, Inc. Annual Meeting of Stockholders
May 10, 2012
Q1 2012 GenVec, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin -100.95% -41.94%
Operating margin -101.23% -42.17%
EBITD margin - -40.85%
Return on average assets -45.10% -21.48%
Return on average equity -51.02% -25.24%
Employees 78 -
Carbon Disclosure Rating - -

Address

65 West Watkins Mill Road
GAITHERSBURG, MD 20878
United States - Map
+1-240-6320740 (Phone)
+1-240-6320735 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

GenVec, Inc. (GenVec), is a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines. A key component of GenVec�s strategy is to develop and commercialize its product candidates through collaborations. GenVec is working with companies and organizations, such as Novartis, Merial, and the United States Government to support a portfolio of product programs that address the prevention and treatment of a number of human and animal health concerns. GenVec�s development programs address therapeutic areas, such as hearing loss, balance disorders, and cancer, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health the Company is developing vaccines against foot-and-mouth disease (FMD).

Officers and directors

Zola P. Horovitz Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation - Reuters
Cynthia Collins President, Chief Executive Officer, Director
Age: 54
Bio & Compensation - Reuters
Douglas J. Swirsky Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary
Age: 42
Bio & Compensation - Reuters
Bryan T. Butman Ph.D. Senior Vice President - Vector Operations
Age: 59
Bio & Compensation - Reuters
Douglas E. Brough Ph.D. Vice President - Head of Research
Age: 57
Bio & Compensation - Reuters
Michael C. Tucker Vice President - Strategy and Legal Affairs
Age: 43
Bio & Compensation - Reuters
Edward M. Connor Jr., M.D. Independent Director
Age: 60
Bio & Compensation - Reuters
Wayne T. Hockmeyer Ph.D. Independent Director
Age: 67
Bio & Compensation - Reuters
William N. Kelley M.D. Independent Director
Age: 72
Bio & Compensation - Reuters
Adel A. F. Mahmoud M.D., Ph.D. Independent Director
Age: 70
Bio & Compensation - Reuters